Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05272813
Other study ID # 2020-001-CN
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date April 28, 2022
Est. completion date September 2025

Study information

Verified date October 2023
Source MingSight Pharmaceuticals, Inc
Contact Ling Yang
Phone +8613421382136
Email yangling@relin.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase I/II, single arm, multi-center, open-label clinical trial of MS-553 in patients with CLL/SLL whose disease relapsed after or was refractory to at lease 1 prior therapy (chemotherapy and/or targeted drug therapy, which must include BTK inhibitor therapy) and who are indicated for treatment per IWCLL2018.


Recruitment information / eligibility

Status Recruiting
Enrollment 48
Est. completion date September 2025
Est. primary completion date April 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age 18 years or older, male or female. - Diagnosis of CLL/SLL per IWCLL2018 criteria. - Patients with relapsed or refractory CLL/SLL who have failed at least 1 prior therapy (chemotherapy and/or targeted drug therapy, which must include BTK inhibitor therapy), are indicated for treatment per IWCLL2018. - Measurable lesions detected by contrast-enhanced computed tomography (CT): at least one lymph node with a maximum axis of more than 1.5 cm and one measurable vertical dimension. - WHO/ECOG performance status of 0 to 2. - Patients with an estimated survival of more than 3 months. Exclusion Criteria: - Biopsy-proven and pathologically confirmed current or past transformation to Richter's syndrome. - Patients with active and uncontrolled autoimmune cytopenia, including autoimmune hemolytic anemia and idiopathic thrombocytopenic purpura. - Patients who have received any of the following treatments within 14 days prior to the first dose: - Major surgery; - Glucocorticoids (at a dose equal to or greater than 20 mg/day prednisone or equivalent), unless used by inhalation, topical or intraarticular route, or unless necessary for premedication before and after iodinated contrast dye. After discussion with the Sponsor, steroid therapy at high doses for an extended period may be allowed under the following circumstances: 1. Treatment of autoimmune hemolysis or autoimmune thrombocytopenia associated with CLL/SLL; 2. Short-term (within 14 days) use to treat inactive infections of diseases unrelated to CLL/SLL (e.g. arthritis, asthma), which results in acute exacerbation, including steroid dose modifications required for adrenal insufficiency; - Cytotoxic chemotherapy or biologic therapy, excepting BCR pathway kinase inhibitors for which a washout of 24 hours prior to the first dose is required. - Toxicity from prior anti-tumor therapy (chemotherapy, radiotherapy, or biotherapy) did not restore to = Grade 1 (except for alopecia); atrial fibrillation from prior treatment with BTK inhibitors did not restore to = Grade 2. - Central nervous system (CNS) leukemia or lymphoma, including a history of asymptomatic, previously treated CNS disease.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
MS-553
MS-553

Locations

Country Name City State
China Peking University People's Hospital Beijing Xicheng District

Sponsors (1)

Lead Sponsor Collaborator
Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of dose limiting toxicities 28 days
Secondary Incidence and severity of adverse events Assessed throughout the study from the time of first dose of study drug until 30 days after the patient's last dose of study drug or until the event has resolved, stabilized, or an outcome reached, whichever comes first regardless of timing of EoT visit
Secondary Overall response rate up to 24 months
Secondary Time to tumor response During intervention
Secondary Disease control rate During intervention
Secondary Progression free survival During intervention
Secondary Overall survival During intervention
Secondary Assessment of minimal residual disease During intervention
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT01804686 - A Long-term Extension Study of PCI-32765 (Ibrutinib) Phase 3
Active, not recruiting NCT03078855 - A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma Phase 3
Recruiting NCT05417165 - Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia Phase 2
Completed NCT02910583 - Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL) Phase 2
Active, not recruiting NCT05023980 - A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Phase 3
Recruiting NCT04553692 - Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers Phase 1
Terminated NCT02877082 - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Phase 2
Completed NCT01699152 - Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Phase 1
Completed NCT01419691 - Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) Phase 2
Completed NCT01161511 - Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia Phase 1
Completed NCT00759603 - Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia Phase 2
Recruiting NCT04965493 - A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Phase 3
Completed NCT01611090 - A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Phase 3
Terminated NCT02258529 - Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma Phase 2
Recruiting NCT05336812 - Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia Phase 2
Recruiting NCT05006716 - A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies Phase 1/Phase 2
Recruiting NCT04545762 - Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma Phase 1
Recruiting NCT03516617 - Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Phase 2
Active, not recruiting NCT03336333 - A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL Phase 3
Completed NCT01973387 - A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma Phase 3